APP Pharmaceuticals to release Chlorothiazide Sodium for Injection APP Pharmaceuticals.

Food and Medication Administration to advertise Chlorothiazide Sodium for Injection, USP. APP expects to release Chlorothiazide Sodium for Injection, USP in the 4th quarter of 2009. According to 2008 IMS data, product sales of this product in the United States were around $51 million1. Chlorothiazide is a diuretic used to treat high blood circulation pressure , and also liquid retention in people who have congestive heart failing, cirrhosis of the liver, kidney disorders, or edema caused by taking estrogen or steroids.The rate of experiencing a food allergy was 59 % higher for obese kids, stated NIEHS researcher Stephanie London, M.D., a co-author on the study. As childhood obesity rates rise, NIEHS shall continue to work to regulate how environmental elements affect this epidemic, stated Linda Birnbaum, Ph.D., NIEHS director. Seeing a possible link between obesity and allergies provides additional inspiration for undertaking the challenge of reducing childhood weight problems. Given that the prevalence of both obesity and allergic disease has increased among children during the last several decades, it is important to understand and, if possible, prevent these epidemics, said Cynthia M. Visness, Ph.D., lead writer on the paper and a scientist at Rho Federal government Systems Division, Inc.